

Clinical trial of safety (reactogenicity) and immunogenicity of needle-free jet injection of reduced-dose, intradermal, Influenza vaccine (INF) administered to more than or equal to six month- to less than 24 month-old infants and toddlers in the Dominican Republic

Submission date 04/10/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 16/04/2007	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 09/01/2020	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Martin Friede

Contact details
World Health Organization (WHO)
20 Avenue Appia
Geneva-27
Switzerland
CH-1211

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00386542

Protocol serial number

Study information

Scientific Title

Clinical trial of safety (reactogenicity) and immunogenicity of needle-free jet injection of reduced-dose, intradermal, Influenza vaccine (INF) administered to more than or equal to six month- to less than 24 month-old infants and toddlers in the Dominican Republic

Study objectives

Intradermal administration of a fraction (40%) of a dose of influenza vaccine with a needle-free injector induces a non-inferior immune response compared to intramuscular injection of a full dose, in infants and toddlers.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from:

1. Dominican Republic: Local ethics committee (Consejo Nacional de Bioética en salud (CONABIOS Universidad Católica Santo Domingo) on 27th June 2006
2. USA: Centres for Disease Control and prevention (CDC) Institutional Review Board on 23rd June 2006
3. Switzerland: World Health Organization Research Ethics Review Committee (WHO ERC) on 28th August 2006

Study design

Clinical research, randomised controlled trial.

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Influenza

Interventions

All volunteers are bled at day of first injection and receive:

Group 1: intramuscular injection with needle 0.25 mL influenza vaccine

Group 2: intramuscular injection with needle 0.1 mL influenza vaccine

Group 3: intradermal injection jet injector 0.1 mL influenza vaccine

All volunteers are bled 28 days after first injection and receive:

Group 1: intramuscular injection with needle 0.25 mL influenza vaccine

Group 2: intramuscular injection with needle 0.1 mL influenza vaccine

Group 3: intradermal injection jet injector 0.1 mL influenza vaccine

All volunteers bled 56 days after first injection and receive:
Groups 2 and 3 (those who received only 0.1 mL doses) receive intramuscular injection of 0.25 mL influenza vaccine.

The Principal Investigator for this trial is:
Bruce Weniger
Centres for Disease Control and prevention (CDC)
1600 Clifton Road (D-26)
Atlanta, GA 30333
United States of America
Telephone: +1 404 639 8779
Email: bgw2@cdc.gov

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Influenza vaccine

Primary outcome(s)

Safety

Key secondary outcome(s)

Immunogenicity

Completion date

01/08/2007

Eligibility

Key inclusion criteria

1. Age from six or older to less than 24 months
2. Born after a full-term pregnancy of gestational age of more than or equal to 37 weeks, and a birth weight of more than or equal to 2.5 kg
3. History of prior or first attendance as a patient, or as a sibling of a patient, seeking routine immunisation or other clinical care at the Hospital Infantil Robert Reid Cabral (HIRRC)
4. Up-to-date for routine doses of vaccines officially recommended for the participants age in the Dominican Republic
5. In good health

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

6 months

Upper age limit

24 months

Sex

Key exclusion criteria

1. Have fever (by parental report or by rectal temperature greater than or equal to 38.5°C or axillary greater than or equal to 38.0°C) currently or within the past three days, or who are currently suffering from an acute or chronic infectious disease
2. Have had an acute or chronic infection requiring systemic antimicrobial therapy (antibiotic or antiviral) or other prescribed treatment within the past 21 days
3. Are malnourished, defined by weight less than two standard deviations below the median weight for their age
4. Are allergic to eggs, or have a history of any anaphylactic shock, asthma, urticaria, or other allergic reaction after previous vaccinations, or have allergy or hypersensitivity to any component of the study vaccine
5. Have ever received previously any influenza vaccine
6. Have received within the prior 28 days, or for whom there is the indication to receive in the next 56 days, any non-study vaccination or investigational agent outside of the study
7. Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time
8. Have currently any serious confirmed or suspected disease, such as metabolic, cardiac, or autoimmune disease, or diabetes
9. Have a history of epilepsy or a seizure disorder, or neurodevelopmental disorders such as autism
10. Have any condition which, in the opinion of the investigator, may interfere in the evaluation of the objectives of the study

Date of first enrolment

01/10/2006

Date of final enrolment

01/08/2007

Locations

Countries of recruitment

Dominican Republic

Switzerland

Study participating centre

World Health Organization (WHO)

Geneva-27

Switzerland
CH-1211

Sponsor information

Organisation

Centers for Disease Control and Prevention

ROR

<https://ror.org/042twtr12>

Funder(s)

Funder type

Government

Funder Name

Centers for Disease Control and Prevention

Alternative Name(s)

United States Centers for Disease Control and Prevention, Centers for Disease Control, U.S. Centers for Disease Control and Prevention, US Centers for Disease Control and Prevention, Centros para el Control y la Prevención de Enfermedades, CDC, U.S. CDC, USCDC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United States of America

Funder Name

PATH

Alternative Name(s)

Program for Appropriate Technology in Health, Program for the Introduction and Adaptation of Contraceptive Technology

Funding Body Type

Government organisation

Funding Body Subtype

Other non-profit organizations

Location

United States of America

Funder Name

World Health Organization (WHO) (Switzerland) (ref: RPC170)

Alternative Name(s)

, , Всемирная организация здравоохранения, Organisation mondiale de la Santé, Organización Mundial de la Salud, WHO, , ВОЗ, OMS

Funding Body Type

Government organisation

Funding Body Subtype

International organizations

Location

Switzerland

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results	Interim results of phase I			No	No